source
- Gene editor Scribe starts second-half IPO spree with $129M listingA nine-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 millionEndpoints · 5d ago↗ source
- Updated: FDA adcomm backs popular wellness peptides, despite staff concernsAn FDA advisory committee voted to recommend expanding access to popular peptides used by health and wellness enthusiasts for repairing muscles, healing injuries, boosting metabolism and reducing i…Endpoints · 5d ago↗ source
- FDA to end pilot aimed at preventing production issuesThe FDA said it will end a pilot that was intended to help drugmakers proactively address production issues. Few companies took advantage of the program during its three-year run. In April 2027, th…